Skip to content

Biodistribution of Tc-99m-BTG-N4 - a retrospective evaluation

Biodistribution of Tc-99m-BTG-N4 - a retrospective evaluation - Tc-99m-BTG-N4

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00030296
Enrollment
5
Registered
2023-03-27
Start date
2021-07-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Biodistibution with 99mTc-BTG-N4

Sponsors

Klinik für Nuklearmedizin, Universitätsklinikum Augsburg
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed prostate carcinoma and an examination with 99mTc-BTG-N4

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
The aim of the retrospective analysis is to determine the biodistribution of the GRPR ligand 99mTc-BTG-N4 and in particular the radiation dose for organs and the whole body. time period: 05.07.2021 - 20.07.2022 Method: The "Volume of Interest" is drawn around the corresponding organs and the activity concentration in the different acquired images is determined. Other clinical parameters and the activity values show the residence time of the radiopharmaceutical in the individual organs.

Countries

Germany

Contacts

Public ContactLuisa Amann

Klinik für Nukelarmedizin

Studien.Nuk@uk-augsburg.de00498214002052

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026